AAP: abiraterone acetate plus prednisone; ADT: androgen-deprivation therapy; AR: androgen receptor; CI: confidence interval; ECOG PS
: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; ITT: intention to treat population; LHRHA: luteinizing hormone releasing hormone antagonist; Ml: metastatic; mCSPC: metastatic castration-sensitive prostate cancer; NR: not reported; NYR: not yet reached; OS: overall survival; PCa: prostate cancer; PFS: progression-free survival; PSA: prostate-specific antigen; rPFS, radiographic progression-free survival; RP: radical prostatectomy; RT: radiation therapy; SOC: standard of care.
Six patients had ECOG PS
0, 21 had ECOG PS
1 and 13 had ECOG PS
Probablythe ECOG PS
was more preserved in exon 19 deletion patients after failure on pemetrexed-carboplatin.
On univariateanalysis, baselineNLR, treatment modality, RMH score, ECOG PS
, and number of metastatic sites did not have significant impact on PFS.
Age more than 75 years, ECOG PS
3 or more, any evidence of distant metastasis, comorbid conditions like hypertension, COPD, cirrhosis, defaulted patients, Haematological parameters like WBC <4000/cu.mm, PC <15000/cu.mm, Serum creatinine >1.5 mg/cu.mm, palliative resection of stomach cancer, histologies other than adenocarcinomas.
Multivariable Cox regression models showed that high Fuhrman grade, ECOG PS
, T stage, and distant metastasis were independently associated with shorter PFS and OS, whereas targeted treatment was independently associated with longer PFS and OS.
After 10 years since the initial diagnosis (July 2013), the patient presented in bad physical condition (ECOG PS
2, severe asthenia, grade 3 dyspnea as per the modified Medical Research Council (mMRC) criteria, and chronic deep vein thrombosis of the upper left leg).
In this multivariate model adjusted for age, ECOG PS
, and the presence of visceral metastases, vaccination therapy was an independent predictive factor for better OS (P = 0.0088).
A common set of criteria for the selection of patients were used by the two centres: advanced hepatocellular carcinoma diagnosed according to the criteria of EASL , not amendable for locoregional treatment (including transcatheter arterial chemoembolization, radio frequency ablation (RFA), and surgery), ECOG PS
0-2, CP A or B, and no substantial co-morbidity (uncontrolled cardio- or cerebrovascular disease, recent bleeding episodes, or active ulcer disease).
Among the 104 patients treated, the baseline characteristics were: median age 68 years (67% age 65 or older); 83% were male; 81% were White; 14% were Asian; ECOG PS
of 0 or 1 ; Child Pugh class and score were A5, A6, B7, and B8 ; 21 % were HBV seropositive and 25% HCV seropositive.
Forty three patients using simple random sampling were selected from Oncology department, outpatient department (OPD) at CMH Rawalpindi with histologically confirmed carcinoma of lung, breast and prostate having age more than or equal to 18 years, including both genders, with Eastern Cooperative Oncology Group Performance Status (ECOG PS
) 1 to 2 and radiological evidence of skeletal metastasis (bone scan and/or radiographs and/or CT Scan and/or MRI scans) causing pain which could be measured objectively by visual analogue scale were included in this study after informed written consent.
On univariable analysis the factors which had the most significant impact on primary PSA progression were ECOG PS
[greater than or equal to]2 (OR 9.14, 95% CI 0.72 to 115.5; p = 0.09), prior abiraterone (OR 0.10, 95% CI 0.01 to 0.87; p=0.04), and receipt of primary prophylaxis with G-CSF (OR 0.08, 95% CI 0.01 to 0.73; p=0.03).